TEVIMBRA (tislelizumab)
Various Solid Tumors
Approved / Phase 3Commercial / Late-stage Development
Key Facts
Indication
Various Solid Tumors
Phase
Approved / Phase 3
Status
Commercial / Late-stage Development
Company
About BeOne Medicines
BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Guardant Infinity Biomarker Discovery | Guardant Health | Development/Commercial |
| Cytotoxic Oncology Generic | MSN Laboratories | Pre‑clinical |
| APCEDEN® | APAC Biotech | Approved |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| 177Lu‑BetaBart (RV‑01) | AtomVie Global Radiopharma | Phase 1/2a |
| BeiGene Oncology Portfolio | EVA Pharma | Phase 2/3 |
| Bevacizumab Biosimilar | Bio Usawa Biotechnology | Preclinical |